Skip to content

Recent Articles

Sally Ross

Chief Marketing Officer departs Lazar

It is with mixed emo­tions that I announce the depar­ture of Kate (Kathryn) Ross, Chief Mar­ket­ing Offi­cer at Lazar Phar­ma­ceu­ti­cals since the com­pa­ny was found­ed in 2001.

Ross and the Lazar Phar­ma­ceu­ti­cals Board of Direc­tors came to a mutu­al agree­ment last evening that effec­tive imme­di­ate­ly they would part ways. I am not at lib­er­ty at this time to dis­cuss the cir­cum­stances sur­round­ing Ross’ depar­ture, or com­ment on rumors that she leaked pro­pri­etary infor­ma­tion relat­ed to the recent dis­ap­pear­ances of two indi­vid­u­als involved in Lazar’s clin­i­cal trials.


Second disappearance an “unfortunate coincidence”

Author­i­ties are inves­ti­gat­ing the dis­ap­pear­ance of a sec­ond indi­vid­ual who was who was enrolled in one of Lazar’s clin­i­cal tri­als. George Lazar, Pres­i­dent and CEO of Lazar Phar­ma­ceu­ti­cals, calls this sec­ond dis­ap­pear­ance “an unfor­tu­nate coin­ci­dence” and reit­er­ates that as of this time, “there have been no charges filed and no accu­sa­tions made regard­ing any crim­i­nal or improp­er activ­ity on behalf of Lazar Pharmaceuticals.”


Decoder ring

Marketing’s first magic numbers

To intro­duce you to the new Lazar Phar­ma­ceu­ti­cals web­site, our Mar­ket­ing Depart­ment has issued a series of “mag­ic num­bers”. The first vis­i­tor to decode the mag­ic num­bers list­ed below will receive a free Lazar Phar­ma brand­ed polo shirt and golf cap. Good luck!

Read moreRead more


Addressing shareholder concerns

Giv­en yes­ter­day’s news about a gov­ern­ment inves­ti­ga­tion that inter­viewed sev­er­al Lazar Phar­ma­ceu­ti­cal employ­ees, com­bined with the recent volatil­i­ty in the stock mar­ket, I would like to address the con­cerns I’ve been hear­ing from our shareholders.

First off, the facts about the gov­ern­ment inves­ti­ga­tion that was revealed on CNBC, CNN and oth­er tele­vi­sion news chan­nels yes­ter­day. This is NOT an inves­ti­ga­tion of Lazar Phar­ma­ceu­ti­cals or any of our cor­po­rate activ­i­ties. Rather, the Naval Crim­i­nal Inves­tiga­tive Ser­vice (NCIS) has ques­tioned sev­er­al Lazar employ­ees in con­nec­tion with the dis­ap­pear­ance of a US Navy mid­ship­man who was enrolled in one of Lazar’s clin­i­cal tri­als.  Read moreRead more